Retrotope is a groundbreaking brand that focuses on developing a new class of drugs to combat disease and cellular degeneration caused by lipid peroxidation (LPO). With their unique understanding of LPO and their innovative technology platform, Retrotope has created a pipeline of first-in-class therapeutic candidates to treat a range of devastating degenerative diseases. Their lead drug candidate, RT001, is currently in late-stage clinical trials for the treatment of several orphan neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Friedreich's ataxia (FA), and infantile neuroaxonal dystrophy (INAD).

Retrotope's exceptional impact is visible through their impressive number of addressable diseases, research programs, clinical programs, collaborators, research institutions, and patients dosed. Guided by a skilled leadership team, including President Anil Kumar, Founder and CSO Mikhail S. Shchepinov, MD CMO Peter G.

Milner, and others, Retrotope is committed to making a positive impact on the future of science and therapeutics. They provide a vibrant and dynamic work environment, welcoming talented individuals who are eager to contribute to their meaningful industry. Explore Retrotope's press releases, news, and videos to stay up to date with their latest advancements